Status:
COMPLETED
A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
Lead Sponsor:
Pfizer
Conditions:
Osteoarthritis
Eligibility:
All Genders
40-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to p...
Eligibility Criteria
Inclusion
- Male or non-pregnant female aged 40-75 with chronic moderate to severe knee pain due to OA (scoring 50 out of 100 on a visual analog scale on knee pain).
- Subjects must meet one of the following: unwilling to take non-opiate pain medications, or for whom non-opiate pain medications have failed, or are candidates for or seeking invasive interventions such as intraarticular injections, knee arthroplasty, or total knee surgery
Exclusion
- History or symptoms of autoimmune disorders, cancer within the last 5 years except for cutaneous basal cell or squamous cell cancer resolved by excision, allergic reaction to monoclonal antibodies or IgG-fusion proteins, Hepatitis B, C or HIV, drug abuse, fibromyalgia, clinically significant cardiac disease, diabetes mellitus requiring oral treatment or insulin, clinically significant neurological disease or clinically significant psychiatric disorders
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00394563
Start Date
March 1 2006
End Date
October 1 2007
Last Update
October 12 2009
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
2
Pfizer Investigational Site
Phoenix, Arizona, United States, 85013
3
Pfizer Investigational Site
Phoenix, Arizona, United States, 85023
4
Pfizer Investigational Site
Tucson, Arizona, United States, 85712